Literature DB >> 7144441

Specific calcium antagonist binding sites in brain.

P J Marangos, J Patel, C Miller, A M Martino.   

Abstract

The binding of the calcium antagonist [3H] nitrendipine ([3H] NDP) to brain and heart is described and the brain site is characterized. The binding is saturable, specific and of very high affinity with KD values of 0.16 nM in brain and 0.21 nM in heart. Our kinetic results are similar to those recently reported by two other groups (1, 2), indicating a saturable, high affinity binding site in brain. In brain the binding sites are enriched in crude nuclear and synaptosomal fractions. The highest levels of binding are seen in the hippocampus, caudate and cerebral cortex with much lower levels in the cerebellum and pons. Calcium has a marked stimulatory effect on [3H] NDP binding at 10(-4) M. Addition of 0.5 mM CaCl2 to EDTA treated membranes nearly doubles the number of binding sites. Of the many drugs and neurotransmitters tested only other calcium antagonists, i.e. verapamil, inhibit binding (IC50 = 250 nM). The inhibition of [3H] NDP binding by verapamil is apparently non-competitive and not complete, suggesting that [3H] NDP binds to several sites, only some of which are inhibited by verapamil. The [3H] NDP binding site is probably a protein since it is very sensitive to trypsin, heat and sulfhydryl reagents.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7144441     DOI: 10.1016/0024-3205(82)90049-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  18 in total

Review 1.  Psychopharmacological properties of calcium channel inhibitors.

Authors:  O Pucilowski
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  The molecular pharmacology and structural features of calcium channels.

Authors:  D R Ferry; A Goll; M Rombusch; H Glossmann
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

3.  Histrionicotoxins: effects on binding of radioligands for sodium, potassium, and calcium channels in brain membranes.

Authors:  T Lovenberg; J W Daly
Journal:  Neurochem Res       Date:  1986-11       Impact factor: 3.996

4.  Calcium channel activation and self-biting in mice.

Authors:  H A Jinnah; S Yitta; T Drew; B S Kim; J E Visser; J D Rothstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

Review 5.  Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  H A Friedel; E M Sorkin
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

6.  Interaction of calcium channel blockers with non-neuronal benzodiazepine binding sites.

Authors:  E H Cantor; A Kenessey; G Semenuk; S Spector
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

7.  Interactions between a "calcium channel agonist", Bay K 8644, and calcium antagonists differentiate calcium antagonist subgroups in K+-depolarized smooth muscle.

Authors:  M Spedding; C Berg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-11       Impact factor: 3.000

Review 8.  Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  K L Goa; E M Sorkin
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

9.  Differential effects of nifedipine, verapamil, and diltiazem on noradrenaline-induced contractions, adrenergic transmitter release, and alpha-adrenoceptor binding in the female rabbit urethra.

Authors:  B Larsson; E D Högestätt; A Mattiasson; K E Andersson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-05       Impact factor: 3.000

10.  Dietary intake of sodium chloride in the rat influences [3H]nitrendipine binding to adrenal glomerulosa cell membranes but does not alter binding to vascular smooth muscle membranes.

Authors:  R J Schiebinger
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.